LivaNova (NASDAQ:LIVN) Given New $60.00 Price Target at Stifel Nicolaus

LivaNova (NASDAQ:LIVN) had its price target decreased by Stifel Nicolaus from $72.00 to $60.00 in a research report released on Wednesday,Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock.

LIVN has been the topic of several other reports. Needham & Company LLC cut their price objective on shares of LivaNova from $75.00 to $64.00 and set a “buy” rating on the stock in a research report on Wednesday. Mizuho cut their price target on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a report on Thursday, October 31st. Robert W. Baird raised their price target on shares of LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. StockNews.com raised LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 14th. Finally, Wolfe Research lowered LivaNova from an “outperform” rating to a “peer perform” rating in a report on Wednesday. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $64.20.

LivaNova Trading Up 1.7 %

LivaNova stock opened at $41.63 on Wednesday. LivaNova has a 12 month low of $40.37 and a 12 month high of $64.47. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. The business’s fifty day simple moving average is $47.40 and its two-hundred day simple moving average is $49.49. The company has a market capitalization of $2.26 billion, a price-to-earnings ratio of 99.12 and a beta of 1.00.

Insider Buying and Selling at LivaNova

In other LivaNova news, Director Francesco Bianchi sold 1,250 shares of the business’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total transaction of $63,737.50. Following the completion of the sale, the director now directly owns 7,522 shares in the company, valued at $383,546.78. The trade was a 14.25 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.27% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On LivaNova

Institutional investors and hedge funds have recently made changes to their positions in the business. Russell Investments Group Ltd. increased its holdings in LivaNova by 17.1% during the fourth quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock valued at $70,000 after buying an additional 219 shares during the last quarter. Sterling Capital Management LLC boosted its stake in shares of LivaNova by 800.6% during the 4th quarter. Sterling Capital Management LLC now owns 1,621 shares of the company’s stock worth $75,000 after acquiring an additional 1,441 shares during the last quarter. Central Pacific Bank Trust Division grew its position in shares of LivaNova by 21.2% during the 4th quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company’s stock valued at $191,000 after acquiring an additional 720 shares during the period. Vestcor Inc purchased a new stake in shares of LivaNova in the 4th quarter worth $204,000. Finally, Optimize Financial Inc bought a new position in LivaNova in the 4th quarter worth $208,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.